
METABOLISM

Clinical and Experimental

LIBRARY USE ONLY
UNIVERSITY OF HAWAII LIBRARY

VOLUME XIX, 1970



HENRY M. STRATTON, INC.

NEW YORK and LONDON

EDITORIAL BOARD

EDITOR-IN-CHIEF

JAMES B. FIELD, *Pittsburgh, Pa.*

CONSULTING EDITORS

SAMUEL SOSKIN, *Beverly Hills, Calif.*

GARFIELD G. DUNCAN, *Philadelphia, Pa.*

ASSOCIATE EDITORS

FREDERIC C. BARTTER, *Bethesda, Md.*

PAUL BECK, *Denver, Colo.*

JOHN BETHUNE, *Los Angeles, Calif.*

EDWIN BIERMAN, *Seattle, Wash.*

EDWARD BIGLIERI, *San Francisco, Calif.*

WALTER BORTZ, *Philadelphia, Pa.*

GEORGE BRAY, *Boston, Mass.*

THADDEUS DANOWSKI, *Pittsburgh, Pa.*

BERNARD DAVIS, *Pittsburgh, Pa.*

LESLIE DEGROOT, *Chicago, Ill.*

JOHN DIETSCHY, *Dallas, Texas*

ALLAN DRASH, *Pittsburgh, Pa.*

JOHN FAIN, *Providence, R. I.*

DANIEL FOSTER, *Dallas, Texas*

BOY FRAME, *Detroit, Mich.*

ANDREW FRANTZ, *New York, N. Y.*

LAWRENCE FROHMAN, *Buffalo, N. Y.*

MARTIN GOLDNER, *Brooklyn, N. Y.*

H. M. GOODMAN, *Boston, Mass.*

GRANT GWINUP, *Orange, Calif.*

RICHARD HAVEL, *San Francisco, Calif.*

DAVID YI-YUNG HSIA, *Maywood, Ill.*

LEO KRALL, *Boston, Mass.*

BERNARD LANDAU, *Cleveland, Ohio*

REED LARSEN, *Pittsburgh, Pa.*

ROGER LESTER, *Boston, Mass.*

RACHMIEL LEVINE, *New York, N. Y.*

DONALD MARTIN, *Boston, Mass.*

THOMAS MERIMEE, *Boston, Mass.*

DANIEL MINTZ, *Miami, Fla.*

JOHN A. MOORHOUSE, *Winnipeg, Canada*

GLENN MORTIMORE, *Hershey, Pa.*

DONALD NELSON, *Salt Lake City, Utah*

MARIA NEW, *New York, N. Y.*

ROBERT NEY, *Chapel Hill, N. C.*

BERT O'MALLEY, *Nashville, Tenn.*

A. RAPOPORT, *Toronto, Canada*

DAVID RIMOIN, *St. Louis, Mo.*

LEON ROSENBERG, *New Haven, Conn.*

STANTON SEGAL, *Philadelphia, Pa.*

LOUIS SHERWOOD, *Boston, Mass.*

STUART SOELDNER, *Boston, Mass.*

JURGEN STEINKE, *Boston, Mass.*

KARL SUSSMAN, *Denver, Colo.*

ARMEN TASHJIAN, *Boston, Mass.*

WILLIAM A. TISDALE, *Burlington, Vt.*

STANLEY ULICK, *Bronx, N. Y.*

JOHN URQUHART, *Pittsburgh, Pa.*

ROBERT UTIGER, *Philadelphia, Pa.*

CECIL WATSON, *Minneapolis, Minn.*

HIBBARD WILLIAMS, *San Francisco, Calif.*

ROBERT WILLIAMS, *Seattle, Wash.*

PETER WOOD, *Palo Alto, Calif.*

RICHARD WURTMAN, *Cambridge, Mass.*

LESLIE ZIEVE, *Minneapolis, Minn.*

Metabolism

Clinical and Experimental

CONTENTS

No. 1 (January)

PLASMA TRIGLYCERIDE RESPONSE TO CARBOHYDRATES, FATS AND CALORIC INTAKE	<i>Paul J. Nestel, Kevin F. Carroll and Nathalie Havenstein</i>	1
URINARY PEPTIDE HYDROXYPROLINE BEFORE AND DURING POSTPARTUM INVOLUTION OF HUMAN UTERUS	<i>LeRoy Klein and Samuel S. C. Yen</i>	19
METABOLISM OF XYLITOL IN HEALTHY SUBJECTS AND PATIENTS WITH RENAL DISEASE	<i>I. M. Spitz, A. H. Rubenstein, I. Bersohn and K. H. Büssler</i>	24
EFFECTS OF THYROTROPIN, SODIUM FLUORIDE AND IONS ON THYROID SLICE METABOLISM	<i>Gerald Burke</i>	35
ACUTE EFFECTS OF IODIDE OR THYROID IN CHRONIC IODINE DEFICIENCY: CHANGES IN THYROID GLAND AND IN SERUM AND PITUITARY THYROTROPIN	<i>V. Abbassi and J. M. McKenzie</i>	43
EFFECTS OF ENTERIC HORMONES ON INSULIN SECRETION	<i>Michael E. Kahil, George R. McIlhaney and Paul H. Jordan, Jr.</i>	50
POSSIBLE PREDISPOSITION OF DIABETIC PATIENTS TO HYPERKALEMIA FOLLOWING ADMINISTRATION OF POTASSIUM-RETAINING DIURETIC AMILORIDE (MK 870)	<i>John L. McNay and Erdogan Oran</i>	58
DIISOPROPYLAMMONIUM DICHLOROACETATE (DIPA) AND SODIUM DICHLOROACETATE (DCA): EFFECT ON GLUCOSE AND FAT METABOLISM IN NORMAL AND DIABETIC TISSUE	<i>Peter W. Stacpoole and James M. Felts</i>	71
SERUM GONADOTROPIN LEVELS DURING MEDICAL STRESS (MYOCARDIAL INFARCTION)	<i>Amelia Guevara, Myron H. Luria and Ralph G. Wieland</i>	79
EFFECTS OF ALLOPURINOL ON HYPERURICEMIA SECONDARY TO FASTING	<i>Joseph Schatanoff, Theodore G. Duncan and Garfield G. Duncan</i>	84
PRELIMINARY REPORT: SERUM LIPID LEVELS IN DIABETES SECONDARY TO CHRONIC PANCREATITIS	<i>B. I. Joffe, L. Krut, S. Bank, I. N. Marks and P. Keller</i>	87

No. 2 (February)

EDITORIAL	91
STUDIES ON RAISED FREE FATTY ACIDS IN HYPERTHYROIDISM <i>Aaron I. Vinik, Bernard L. Pimstone and Raymond Hoffenberg</i>	93
GROWTH HORMONE LEVELS IN SEVERE RENAL FAILURE <i>Naguib A. Samaan and Richard M. Freeman</i>	102
SERUM FUCOSE LEVELS AND THEIR RESPONSE TO GLUCOSE LOADING IN DIABETICS <i>A. M. Marshall, R. J. Georges, B. F. Clarke, L. G. Whitby and L. J. P. Duncan</i>	114
LIPID LOWERING INFLUENCE OF ETHYL P-CHLOROPHENOXYISOBUTYRATE IN LIVER OF RATS FED HIGH FAT DIETS <i>Mohan G. Kokatnur and Gray T. Malcom</i>	120
INCREASED URINARY PHOSPHATE EXCRETION FOLLOWING VOLUME EX- PANSION IN NORMAL MAN <i>Thomas H. Steele</i>	129
RELATIONSHIPS OF ATP TO FATTY LIVER: EFFECTS OF ADENINE ANALOGUE, 4-AMINOPYRAZOLOPYRIMIDINE ON LIPID METABOLISM IN RAT LIVER <i>Vittoria Ottani, Paolo Puddu, Paolo Zanetti and Mario Marchetti</i>	140
DISTRIBUTION OF PROTEIN-BOUND ZINC IN NORMAL AND CIRRHOTIC SERUM <i>John D. Boyett and James F. Sullivan</i>	148
EFFECT OF GLUCOCORTICOIDS ON PLASMA GROWTH HORMONE IN MAN <i>John N. Stiel, Donald P. Island and Grant W. Liddle</i>	158
SEQUENTIAL STUDY OF ARGININE MONOCHLORIDE AND NORMAL SALINE AS STIMULI TO GROWTH HORMONE RELEASE <i>Robert Penny, Robert M. Blizzard and Walter T. Davis</i>	165
GLUCOSE INTOLERANCE MECHANISM AFTER STARVATION <i>Manuel Tzagournis and Thomas G. Skillman</i>	170
AMINO ACID CONTENT OF MUSCLE AND PLASMA WITH ALTERED pH <i>William R. Sanslone, Edward Muntwyler, Leo Kesner and Grace E. Griffin</i>	179

No. 3 (March)

FULLER ALBRIGHT, M.D. (1900-1969)	<i>Philip H. Henneman</i>	187
PRELIMINARY REPORT: EFFECT OF DIETARY PYRIDOXINE DEFICIENCY ON EXPERIMENTAL PORPHYRIA <i>Bruce A. Chabner, Jeffrey A. Stein and Donald P. Tschudy</i>		189
STUDIES OF MECHANISM OF CYPROHEPTADINE-INDUCED WEIGHT GAIN IN HUMAN SUBJECTS <i>John N. Stiel, Grant W. Liddle and William W. Lacy</i>		192

EFFECTIVENESS OF MODIFIED GIOVANNETTI DIET COMPARED WITH MIXED LOW-PROTEIN DIET
P. L. Wright, P. J. Brereton and D. E. M. Snell 201

EFFECT OF INTRADUODENAL INSTILLATION OF HYDROCHLORIC ACID ON PLASMA INSULIN LEVELS OF PATIENTS WITH PORTOCAVAL SHUNTS
H. Kaess, G. Schlierf and J. G. von Mikulicz-Radecki 214

EFFECT OF α -ADRENERGIC BLOCKADE ON INSULIN SECRETION IN MAN
Maria G. Buse, Allen H. Johnson, Denis Kuperminc and John Buse 219

DIURNAL VARIATION OF LIVER GLYCOGEN AND PLASMA FREE FATTY ACIDS IN RATS FED AD LIBITUM OR SINGLE DAILY MEAL
Ray W. Fuller and Erol R. Diller 226

HYPOTHALAMICALLY INDUCED HYPERLIPIDEMIA: PROTECTION BY PENTA-ERYTHRITOL TETRANITRATE*William H. Gutstein, Daniel J. Schneck, Gregory Farrell and Willie Long, Jr.* 230

STUDIES IN GLYCOGEN STORAGE DISEASE. IV. LEUKOCYTE PHOSPHORYLASE IN A FAMILY WITH TYPE VI GSD ...*David Schwartz, Michael Savin, Allan Drash and James Field* 238

EFFECT OF AGE OF RAT ON DEVELOPMENT OF HEPATIC CARRIERS FOR BILIRUBIN: A POSSIBLE EXPLANATION FOR PHYSIOLOGIC JAUNDICE AND HYPERBILIRUBINEMIA IN THE NEWBORN ..*Gerold M. Grodsky, Helmut J. Kolb, Rudolph E. Fanska and Catherine Nemecek* 246

UTILIZATION OF EXOGENOUS UREA NITROGEN IN MALNOURISHED ADULTS
Kshetrabasi Tripathy, Saulo Klahr and Hernán Lotero 253

No. 4 (April)

EXPERIMENTALLY INDUCED HYPERKETONEMIA AND INSULIN SECRETION IN THE DOG*F. Xavier Pi-Sunyer, Robert G. Campbell and Sami A. Hashim* 263

STUDIES OF THE MECHANISM OF CARBOHYDRATE INTOLERANCE PRODUCED BY FASTING*Richard J. Mahler and Olga Szabo* 271

REFERENCE STANDARDS FOR CORTISOL PRODUCTION AND 17-HYDROXY-CORTICOSTEROID EXCRETION DURING GROWTH: VARIATION IN THE PATTERN OF EXCRETION OF RADIOLABELED CORTISOL METABOLITES
Frederic M. Kenny, Catherine Richards and Floyd T. Taylor 280

EFFECT OF EXPANSION OF EXTRACELLULAR FLUID VOLUME ON PROXIMAL SODIUM REABSORPTION IN HYPONATREMIC DOGS .*Bernard B. Davis, Franklyn G. Knox, Fred S. Wright and Stuart S. Howards* 291

URINARY INSULIN II. EXCRETION IN CHILDREN AND ADULTS
Samir S. Najjar and Leila Stephan 301

STUDY OF HEREDITARY METABOLIC DISEASES USING IN VITRO TECHNIQUES*David Yi-Yung Hsia* 309

No. 5 (May)

STEROID OUTPUT IN HEALTHY YOUNG MEN OF COLLEGE AGE <i>Benjamin J. Murawski, Kenneth J. Jones and William J. Reddy</i>	341
STUDIES ON ETHANOL-INDUCED STIMULATION OF GLUCOSE-6-PHOSPHATASE ACTIVITY <i>P. Nelson, S. R. Wagle and J. Ashmore</i>	349
TRIAL OF MANNOHEPTULOSE IN MAN <i>Brian F. Johnson and Frederick W. Wolff</i>	354
CIRCADIAN RHYTHM OF HUMAN URINARY AMINO ACID EXCRETION IN FED AND FASTED STATES <i>D. A. Tewksbury and F. N. Lohrenz</i>	363
STUDY OF SERUM INSULIN IN ATHEROSCLEROTIC PATIENTS WITH ENDOGENOUS HYPERTRIGLYCERIDEMIA (TYPES III AND IV HYPERLIPOPROTEINEMIA) <i>Peter T. Kuo and Louise Y. Feng</i>	372
PATHOGENESIS OF METHIONINE-INDUCED TOXICITY <i>David F. Hardwick, Derek A. Applegarth, Donald M. Cockcroft, Patricia M. Ross and Robert J. Calder</i>	381
TIME SEQUENCE OF MACROMOLECULE SYNTHESIS IN EXPERIMENTAL NEPHROSIS <i>Julian B. Marsh, David L. Drabkin and Larissa Poppe</i>	392

No. 6 (June)

MORPHOLOGIC STUDIES OF THE THYMUS IN ACROMEGALY, DIABETES MELLITUS, AND CUSHING'S SYNDROME <i>Jacques V. Souadjian, George D. Molnar, Murray N. Silverstein and Jack L. Titus</i>	401
PRELIMINARY REPORT: PLASMA GROWTH HORMONE IN HYPERTHYROIDISM AND OBESITY: EFFECT OF PROPRANOLOL INFUSION <i>Yuzuru Kato, Masachika Morimoto and Hiroo Imura</i>	406
EARLY INSULIN RESPONSES TO GLUCOSE AND TO TOLBUTAMIDE IN MATURITY-ONSET DIABETES <i>Nora Varsano-Aharon, Elsa Echemendia, Rosalyn S. Yalow and Solomon A. Berson</i>	409
RELATIONSHIPS BETWEEN OXYGEN CONSUMPTION AND BODY COMPOSITION OF OBESE PATIENTS <i>G. Bray, M. Schwartz, R. Rozin and J. Lister</i>	418
STIMULATION OF THYROID ADENYL CYCLASE ACTIVITY AND CYCLIC ADENOSINE 3'5'-MONOPHOSPHATE BY LONG-ACTING THYROID STIMULATOR <i>Toshio Kaneko, Uriel Zor and James B. Field</i>	430
EVALUATION OF INTERRELATIONSHIP BETWEEN CALCIUM AND SODIUM EXCRETION BY CANINE KIDNEY <i>Bernard B. Davis and H. V. Murdaugh</i>	439
TUMOR HYPOGLYCEMIA: A HETEROGENEOUS DISORDER <i>R. A. Kreisberg and L. F. Pennington</i>	445

- CORRELATION OF EFFECTS OF THYROTROPIN, PROSTAGLANDINS AND IONS ON GLUCOSE OXIDATION, CYCLIC-AMP, AND COLLOID DROPLET FORMATION IN DOG THYROID SLICES *Andrew Dekker and James B. Field* 453
- PRELIMINARY REPORT: TRYPTOPHAN: ABNORMAL METABOLISM IN PELLAGRA PATIENTS *L. V. Hanks, J. E. Leklem, R. R. Brown and R.C.P.M. Mekel* 465

No. 7 (July)

- CORTISOL RESPONSES TO DIAZOXIDE IN MAN AND THEIR POSSIBLE RELATIONSHIP TO EFFECTIVE BLOOD VOLUME *Edward N. Ehrlich* 469
- AN IN VITRO EFFECT OF TRIIODOTHYRONINE ON LIPOLYSIS, CYCLIC AMP-C¹⁴ ACCUMULATION AND OXYGEN CONSUMPTION IN ISOLATED FAT CELLS *David R. Challoner and Donald O. Allen* 480
- ATTEMPTS TO AUGMENT THYROTROPIN SECRETION: EFFECTS OF METHIMAZOLE, METHIMAZOLE-IODIDE, VASOPRESSIN, AND GLUCAGON
Clark T. Sawin, Jerome M. Hershman, Stanley D. Handler and Robert D. Utiger 488
- QUARTER CENTURY VICTORY MEDAL FOR DIABETES: A FOLLOW-UP OF PATIENTS ONE TO 20 YEARS LATER *Jerome R. Ryan, Marios C. Balodimos, Bernard I. Chazan, Howard F. Root, Alexander Marble, Priscilla White and Allen P. Joslin* 493
- URINARY CALCIUM EXCRETION DURING KETOACIDOSIS OF PROLONGED TOTAL STARVATION *Jacqueline Garnett, E. S. Garnett, R. J. Mardell and D. L. Barnard* 502
- NONSUPPRESSIBLE INSULIN-LIKE ACTIVITY: IMMUNOCHEMICAL AND PHYSICOCHEMICAL EVIDENCE AGAINST ITS PANCREATIC ORIGIN
Phillip L. Poffenbarger, Antonio Espinosa de los Monteros Mena and Jurgen Steinke 509
- ETHANOL-INDUCED HYPOGLYCEMIA IN THYROXINE-TREATED RATS
Reino H. Ylikahri 518
- EFFECT OF JEJUNOILEOSTOMY ON GLUCOSE AND INSULIN METABOLISM IN TEN OBESE PATIENTS *Jens F. Rehfeld, Erik Juhl and Flemming Quaade* 529
- EFFECTS OF DECAFFEINATED AND NONDECAFFEINATED COFFEE INGESTION ON BLOOD GLUCOSE AND PLASMA RADIOIMMUNOREACTIVE INSULIN RESPONSES TO RAPID INTRAVENOUS INFUSION OF GLUCOSE IN NORMAL MAN *A. Wachman, R. S. Hattner, Barbara George and D. S. Bernstein* 539
- STIMULATORY EFFECT OF EXOGENOUS CATECHOLAMINES ON PLASMA GHG CONCENTRATIONS IN PRESENCE OF BETA ADRENERGIC BLOCKADE *William G. Blackard and Gerald J. Hubbell* 547

No. 8 (August)

INSULIN-DEPENDENT DIABETES MELLITUS AND FRIEDREICH'S ATAXIA IN SIBLINGS	<i>Stephen Podolsky and William A. Sheremata</i>	555
COMPARATIVE EFFECT OF EXPERIMENTAL INJURY AND HYDROCORTISONE INJECTION ON LIVER AND PLASMA COMPOSITION OF RATS <i>Helena Gilder, Mira Valcic, Victor DeLeon and Dora Sternberg</i>		562
ENDEMIC GOITER IN GREECE: EFFECTS OF IODIZED OIL INJECTION <i>B. Malamos, D. A. Koutras, J. Mantzos, L. Chiotak, J. Sfontouris, S. N. Papadopoulos, G. A. Rigopoulos, A. D. Pharmakiotis and G. Vlassis</i>		569
EFFECT OF L-ASPARAGINASE ON CARBOHYDRATE METABOLISM <i>John P. Whitecar, Jr., Gerald P. Bodey, C. Stratton Hill, Jr., and Naguib A. Samaan</i>		581
DEHYDROGENATION OF GLUCOSE AND XYLOSE CATALYZED BY RAT AND SHEEP LIVER MICROSOMAL AND SOLUBLE FRACTIONS <i>Robert P. Metzger, E. F. F. Copp, Silvia A. Metzger and Arne N. Wick</i>		587
TRANSFER OF PLASMA LIPID TO PLATELETS BY ACTION OF GLUCAGON <i>Raymond Caren and Lucille Corbo</i>		598
ACUTE SYMPTOMATIC KETOACIDOSIS FOLLOWING GROWTH HORMONE ADMINISTRATION IN PROLONGED FASTING	<i>Ernst J. Drenick, Ernest M. Gold and Harold Elrick</i>	608
EFFECT OF EPINEPHRINE AND MANNOHEPTULOSE ON EARLY AND LATE PHASES OF GLUCOSE-STIMULATED INSULIN RELEASE <i>Ake Lernmark and Bo Hellman</i>		614
ROLE OF POSTURE IN SODIUM, WATER, AND POTASSIUM HOMEOSTASIS OF AN ABNORMAL PREGNANCY	<i>Marshall D. Lindheimer and Jacques Roux</i>	619
THE EFFECT OF PHYSICAL TRAINING ON INSULIN PRODUCTION IN OBESITY <i>Per Björntorp, Kristina de Jounge, Lars Sjöström and Lars Sullivan</i>		631
CORRESPONDENCE		639

No. 9 (September)

LIPID MOBILIZING FACTOR FROM THE HYPOTHALAMUS <i>T. W. Redding and A. V. Schally</i>		641
ADULT LEAN BODY MASS DECLINES WITH AGE: SOME LONGITUDINAL OBSERVATIONS	<i>Gilbert B. Forbes and Julio C. Reina</i>	653
EFFECT OF ACUTE ETHANOL INTAKE ON PLASMA 11 HYDROXYCORTICOSTEROID LEVELS	<i>Samuel Bellet, Laurian Roman, Oscar DeCastro and Manuel Herrera</i>	664

ROLE OF SYNALBUMIN INSULIN ANTAGONIST IN PATHOGENESIS OF DIA-
BETES MELLITUS *Mayer B. Davidson and Philip L. Poffenbarger* 668

GLUCOSE TOLERANCE AND TIME SEQUENCE OF ADIPOSITY, HYPERIN-
SULINEMIA AND HYPERGLYCEMIA IN OBESE-HYPERGLYCEMIC MICE
(OBOB) *C. Chlouverakis, E. F. Dade and R. A. L. Batt* 687

EFFECT OF VASOPRESSIN ON RENAL CYCLIC AMP GENERATION IN PO-
TASSIUM DEFICIENCY AND PATIENTS WITH HEMOGLOBIN
*L. Gregory Pawlson, Andrew Taylor, Daniel H. Mintz, James B. Field
and Bernard B. Davis* 694

CHARACTERISTICS OF GALACTOSE-1-PHOSPHATE URIDYL TRANSFERASE IN
INTESTINAL MUCOSA OF NORMAL AND GALACTOSEMIC HUMANS
*Shirley Rogers, Philip G. Holtzapple, William J. Mellman
and Stanton Segal* 701

COMPLICATIONS OF DIURETIC THERAPY: SEVERE ALKALOSIS AND SYN-
DROME RESEMBLING INAPPROPRIATE SECRETION OF ANTIDIURETIC
HORMONE *Frederick R. DeRubertis, Michael F. Michelis,
Nama Beck and Bernard B. Davis* 709

No. 10 (October)

Festschrift in Honor of
E. B. ASTWOOD, M.D., C.M., Ph.D.

Carl E. Cassidy, M.D., *Guest Editor*

A collection of papers presented at The New
England Medical Center Hospital, Boston,
Massachusetts, on May 1, 1970, by former
fellows and colleagues

TRIBUTE *Former Fellows and Colleagues* 721

Thyroid

IN VITRO INFLUENCE OF THYROTROPIN OR LONG-ACTING THYROID STIMU-
LATOR ON MOUSE THYROID MEMBRANE POTENTIAL
N. Konno and J. M. McKenzie 724

DIFFERENCE BETWEEN THYROID STIMULATOR IN HYDATIDIFORM MOLE
AND HUMAN CHORIONIC THYROTROPIN *Jerome M. Hershman,
H. Patrick Higgins and Willard R. Starnes* 735

THYROID SUPPRESSION TEST AS INDEX OF OUTCOME OF HYPERTHY-
ROIDISM TREATED WITH ANTITHYROID DRUGS . . . *Carl E. Cassidy* 745

HYPOTHYROIDISM IN PATIENTS WITH GOITER *Carl E. Cassidy
and Richard L. Eddy* 751

THYROID GLAND IN GRAVES' DISEASE: VICTIM OR CULPRIT?
*Inder J. Chopra, David H. Solomon, Delores E. Johnson
and Usha Chopra* 760

DIFFERENCES IN COMPOSITION AND FUNCTION OF IODINATED SUBSTANCES IN STIMULATED THYROID GLANDS	<i>Lester Van Middlesworth and William A. Murphy, Jr.</i>	773
PURIFICATION OF IODOTYROSINE DEIODINASE FROM BOVINE THYROID	<i>Isadore N. Rosenberg</i>	785
<i>Hormone Action</i>		
URINARY EXCRETION OF 3',5'-AMP IN SYNDROMES CONSIDERED REFRAC- TORY TO PARATHYROID HORMONE . . .	<i>G. D. Aurbach, Robert Marcus, Richard N. Winickoff, Ervin H. Epstein, Jr., and Thomas P. Nigra</i>	799
STUDIES ON AN ACTH-ACTIVATED ADENYL CYCLASE FROM A MOUSE ADRENAL TUMOR . .	<i>Ira Pastan, W. Pricer and J. Blanchette-Mackie</i>	809
EFFECT OF AMINOGLUTETHIMIDE AND RESERPINE ON THE HUMAN PITUITARY-ADRENAL AXIS: REMISSION OF A CASE OF CUSHING'S DISEASE . .	<i>James R. Givens, Alvro Camacho and Phillip Patterson</i>	818
CUSHING'S SYNDROME CAUSED BY ACTH- AND CALCITONIN-SECRETING MEDULLARY CARCINOMA OF THE THYROID	<i>K. E. W. Melvin, A. H. Tashjian, Jr., C. E. Cassidy and J. R. Givens</i>	831
<i>Lipids</i>		
LIPOGENESIS IN ADIPOSE TISSUE FROM GENETICALLY OBESE RATS	<i>George A. Bray, Wayne S. Barry and Stella Mothon</i>	839
ANTILIPOLYTIC EFFECTS OF GROWTH HORMONE . .	<i>H. Maurice Goodman</i>	849
RELATION OF FAT CELL ATP CONTENT TO LIPOLYSIS INDUCED BY DIBUTYRYL 3', 5', CYCLIC AMP	<i>C. H. Hollenberg and R. L. Patten</i>	856
QUANTIFICATION OF INTESTINAL FUNCTIONS DURING FASTING: ESTIMA- TIONS OF BILE SALT TURNOVER, FECAL CALCIUM AND NITROGEN EXCRETIONS	<i>Malcolm M. Stanley</i>	865
<i>Pituitary</i>		
PHYSIOLOGICAL FACTORS REGULATING SECRETION OF NEUROPHYSIN	<i>K. W. Cheng and H. G. Friesen</i>	876
IMPLICATIONS OF GROWTH HORMONE RELEASE IN SLEEP	<i>W. P. VanderLaan, D. C. Parker, L. G. Rossman and E. F. VanderLaan</i>	891
A COMPARISON OF RESPONSE OF SERUM GROWTH HORMONE TO GLU- CAGON VASOPRESSIN	<i>Clark T. Swain and Marvin L. Mitchell</i>	898
EFFECT OF EXOGENOUS GLUCAGON ON PITUITARY POLYPEPTIDE HOR- MONE RELEASE	<i>Richard L. Eddy, A. Lloyd Jones and Roberto M. Hirsch</i>	904
BIBLIOGRAPHY OF E. B. ASTWOOD		913

No. 11 (November)

CRITIQUE OF MULTICOMPARTMENTAL ANALYSIS OF CALCIUM KINETICS IN MAN BASED ON STUDY OF 27 CASES	<i>Harvey C. Gonick and Morton Brown</i>	919
--	--	-----

QUANTITATIVE AND QUALITATIVE EFFECTS OF L-TRIIODOTHYRONINE IN
MASSIVE OBESITY*Dorothy R. Hollingsworth,*
Thomas T. Amatruda, Jr. and Robert Scheig 934

GYNecomASTIA AND MASTOPLASIA IN GRAVES' DISEASE . .*Fuad S. Ashkar,*
William M. Smoak, III, Albert J. Gilson and Robert Miller 946

RENAL ELECTROLTE CYCLES AND MECHANISM OF NOCTURIA IN PRIMARY
ALDOSTERONISM*Anthony H. Vagnucci, Alvin P. Shapiro*
and Robert McDonald, Jr. 952

EFFECT OF NICOTINIC ACID ADMINISTRATION ON PLASMA HGH, FFA
AND GLUCOSE IN OBESE SUBJECTS AND IN HYPOPITUITARY PATIENTS
Minoru Irie, Toshio Tsushima and Maki Sakuma 972

GLUCO-REGULATORY HORMONE RESPONSE TO 2-DEOXY-d-GLUCOSE IN-
FUSION IN NORMAL SUBJECTS AT BEDREST . . .*Richard L. Lipman,*
Frode Ulvedal, Joel J. Schnure, Edwin M. Bradley
and Frank R. Lecocq 980

CONVERSION OF GLUCOSE TO LIPID BY HUMAN ADIPOSE TISSUE IN VITRO
Ali M. Mellati, John C. Beck, John Dupre and David Rubinstein 988

ADIPOSE TISSUE METABOLISM OF WEANLING RATS AFTER DESTRUCTION
OF VENTROMEDIAL HYPOTHALAMIC NUCLEI: EFFECT OF HYPOPHY-
SECTOMY AND GROWTH HORMONE*Jack K. Goldman,*
J. David Schnatz, Lee L. Bernardis and Lawrence A. Frohman 995

CORRESPONDENCE 1006

BOOK REVIEW 1009

No. 12 (December)

EFFECT OF TRI-HYDROXYMETHYL-AMINOMETHANE (TRIS) ON INSULIN
SECRETION IN VITRO*Ivo Broeckaert* 1011

STREPTOZOTOCIN DIABETES IN PREGNANT AND NONPREGNANT RATS
Erich K. Golob, Surendra Rishi, Kenneth L. Becker
and Charles Moore 1014

EFFECT OF UNSATURATED DIETARY FAT ON PLASMA LIPOPROTEIN LIPASE
ACTIVITY IN NORMAL AND HYPERLIPIDEMIC STATES
John D. Bagdade, William R. Hazzard and Julianne Carlin 1020

EFFECTS OF OROTIC ACID ON PURINE AND LIPOPROTEIN METABOLISM IN
MAN*William N. Kelley, Martin L. Greene, Irving H. Fox,*
Frederick M. Rosenbloom, Robert I. Levy and J. Edwin Seegmiller 1025

ETHANOL-INDUCED CHANGES IN HEPATIC α -GLYCEROPHOSPHATE AND TRI-
GLYCERIDE CONCENTRATIONS IN NORMAL AND THYROXINE-TREATED
RATS*Reino H. Ylikahri* 1036

HEPATIC EFFECTS OF SULFONYLUREAS
Alexander Marshall, Ronald L. Gingerich and Peter H. Wright 1046

- UREA METABOLISM IN PATIENTS WITH CHRONIC RENAL FAILURE: INFLUENCE OF SODIUM BICARBONATE OR SODIUM CHLORIDE ADMINISTRATION*P. M. Blom van Assendelft and E. J. Dorhout Mees* 1053
- ELECTRORETINOGRAM IN SUCROSE- AND STARCH-FED RATS
.....*A. M. Cohen, H. Freund and E. Auerbach* 1064
- GALACTORRHEA AND PARKINSON-LIKE SYNDROME: AN ADVERSE EFFECT OF α -METHYLDOPA*Rama A. Vaidya, Ashok B. Vaidya, Melvin H. Van Woert and Nathan G. Kase* 1068
- EFFECT OF PROLONGED BED REST ON BONE MINERAL
.....*Charles L. Donaldson, Stephen B. Hulley, John M. Vogel, Robert S. Hattner, Jon H. Bayers and Donald E. McMillan* 1071
- CONVERSION OF INGESTED CARBOHYDRATE-¹⁴ C INTO GLYCEROL AND FATTY ACIDS OF SERUM TRIGLYCERIDE IN PATIENTS WITH MYOCARDIAL INFARCTION*Yoshisuke Maruham* 1085
- ORAL AND INTRAVENOUS D-RIBOSE AND PLASMA INSULIN IN HEALTHY HUMANS: EFFECTS OF ROUTE OF ADMINISTRATION AND OF EPI-INDUCED SODIUM CONSERVATION*Francis X. Schloeder and Frederick C. Goetz* 1094
- EFFECTS OF NUCLEOTIDES POSSESSING A 3', 5'-CYCLIC MONOPHOSPHATE ON ADRENAL STEROIDOGENESIS*D. Mahaffee and R. L. Ney* 1104
- EFFECTS OF CHLORPROMAZINE, PROPRANOLOL AND PHOSPHOLIPASE C ON THYROTROPIN AND PROSTAGLANDIN STIMULATION OF ADENYL CYCLASE-CYCLIC AMP SYSTEM IN DOG THYROID SLICES
.....*Kamejiro Yamashita, Gail Bloom, Barbara Rainard, Uriel Zor and James B. Field* 1109
- RENAL TUBULAR SITES OF NATRIURESIS OF FASTING AND GLUCOSE-INDUCED SODIUM CONSERVATION*Francis X. Schloeder and Bobby J. Steinbaugh* 1119

ANNUAL INDICES

Author Index

- Abbassi, V., 43
 Allen, D. O., 480
 Amatruda, Jr., T. T., 934
 Applegarth, D. A., 381
 Ashkar, F. S., 946
 Ashmore, J., 349
 Astwood, E. B., 913
 Auerbach, E., 1064
 Aurbach, G. D., 799

 Bagdade, J. D., 1020
 Balodimos, M. C., 493
 Bank, S., 87
 Barnard, D. L., 502
 Barry, W. S., 839
 Bassler, K. H., 24
 Batt, R. A. L., 687
 Bayers, J. H., 1071
 Beck, J. C., 988
 Beck, N., 709
 Becker, K. L., 1014
 Bellet, S., 664
 Bernardis, L. L., 995
 Bernstein, D. S., 539
 Bersohn, I., 24
 Berson, S. A., 409
 Björntorp, P., 631
 Blackard, W. G., 547
 Blanchette-Mackie, J., 809
 Blizzard, R. M., 165
 Bloom, G., 1109
 Bodey, G. P., 581
 Boyett, J. D., 148
 Bradley, E. M., 980
 Bray, G., 418
 Bray, G. A., 839
 Brereton, P. J., 201
 Broeckaert, I., 1011
 Brown, M., 919
 Brown, R. R., 465
 Burke, G., 35
 Buse, J., 219
 Buse, M. G., 219

 Campbell, R. G., 263
 Calder, R. J., 381
 Camacho, A., 818
 Caren, R., 598
 Carlin, J., 1020
 Carroll, K. F., 1
 Cassidy, C. E., 745, 751, 831
 Chabner, B. A., 189

 Challoner, D. R., 480
 Chazan, B. I., 493
 Cheng, K. W., 876
 Chiotak, L., 569
 Chlouverakis, C., 687
 Chopra, I. J., 760
 Chopra, U., 760
 Clarke, B. F., 114
 Cockcroft, D. M., 381
 Cohen, A. M., 1064
 Copp, E. F. F., 587
 Corbo, L., 598

 Dade, E. F., 687
 Davidson, M. B., 668
 Davis, B. B., 291, 439, 694, 709
 Davis, W. T., 165
 DeCastro, O., 664
 de Jonghe, K., 631
 Dekker, A., 453
 DeLeon, V., 562
 DeRubertis, F. R., 709
 Diller, E. R., 226
 Donaldson, C. L., 1071
 Drabkin, D. L., 392
 Drash, A., 238
 Drenick, E. J., 608
 Duncan, G. G., 84
 Duncan, L. J. P., 114
 Duncan, T. G., 84
 Dupre, J., 988

 Echemendia, E., 409
 Eddy, R. L., 751
 Eddy, R. L., 904
 Ehrlich, E. N., 469
 Elrick, H., 608
 Epstein, Jr., E. H., 799
 Espinosa de los Monteros Mena, A., 509

 Fanska, R. E., 246
 Farrell, G., 230
 Felts, J. M., 71
 Feng, L. Y., 372
 Field, J., 238
 Field, J. B., 430, 453, 694, 1109
 Forbes, G. B., 653
 Fox, I. H., 1025
 Freeman, R. M., 102

 Freund, H., 1064
 Friesen, H. G., 876
 Frohman, L. A., 995
 Fuller, R. W., 226

 Garnett, E. S., 502
 Garnett, J., 502
 George, B., 539
 Georges, R. J., 114
 Gilder, H., 562
 Gilson, A. J., 946
 Gingerich, R. L., 1047
 Givens, J. R., 818, 831
 Goetz, F. C., 1094
 Gold, E. M., 608
 Goldman, J. K., 995
 Golob, E. K., 1014
 Gonick, H. C., 919
 Goodman, C., 1094
 Goodman, H. M., 849
 Greene, M. L., 1025
 Griffin, G. E., 179
 Grodsky, G. M., 246
 Guevara, A., 79
 Gutstein, W. H., 230

 Handler, S. D., 488
 Hanks, L. V., 465
 Hardwick, D. F., 381
 Hashim, S. A., 263
 Hattner, R. S., 539, 1071
 Havenstein, N., 1
 Hazzard, W. R., 1020
 Hellman, B., 614
 Henneman, P. H., 187
 Herrera, M., 664
 Hershman, J. M., 488, 735
 Higgins, H. P., 735
 Hill, Jr., C. S., 581
 Hirsch, R. M., 904
 Hoffenberg, R., 93
 Hollenberg, C. H., 856
 Hollingsworth, D. R., 934
 Holtzapple, P. G., 701
 Howards, S. S., 291
 Hsia, D. Y., 309
 Hubbell, G. J., 547
 Hulley, S. B., 1071

 Imura, H., 406
 Irie, M., 972
 Island, D. P., 158

- Alkalosis, from diuretics, 709-717
- Allopurinol, affecting hyperuricemia in fasting, 84-86
- Allylisopropylacetamide, and hepatic ALA-synthetase, 189-191
- Amiloride in diabetes, hyperkalemia after, 58-68
- Amino acids
excretion of, food intake affecting, 363-370
metabolism disorders, in vitro studies of, 309-316
in muscle and plasma, pH affecting, 179-185
- Aminogluthethimide, and pituitary-adrenal function, 818-830
- Amino levulinic acid synthetase, hepatic levels in pyridoxine deficiency, 189-191
- 4-Aminopyrazolopyrimidine, affecting lipid metabolism in liver, 140-146
- Amniotic fluid cell cultures, for studies of hereditary metabolic diseases, 309-335
- Andersen's disease, in vitro studies of, 320
- Arginine infusions, affecting growth hormone levels, 165-168
- Argininosuccinic aciduria, in vitro studies of, 313
- L-Asparaginase, affecting carbohydrate metabolism, 581-586
- Astwood, E. B., 721-722, 913-918
- Ataxia, Friedreich's, and diabetes in siblings, 555-559
- Atherosclerosis with hypertriglyceridemia, insulin levels in, 372-378
- Basal cell nevus syndrome, and excretion of cyclic AMP, 799-807
- Basal ganglia calcification, and excretion of cyclic AMP, 799-807
- Bedrest
absolute, endocrine function in, 980-986
prolonged, affecting bone mineral, 1071-1082
- Bicarbonate therapy, affecting urea metabolism in renal failure, 1053-1062
- Bile salt function, during fasting, 865-874
- Bilirubin, hepatic carriers for, 246-252
- Blood volume, and cortisol responses to diazoxide, 469-478
- Body composition
changes in fasting and refeeding, 1006-1008
decline of lean body mass with age, 653-661
and oxygen consumption in obesity, 418-428
- Bone mineral, immobilization affecting, 1071-1082
- Book review: International Symposium on Amphetamines and Related Compounds (*Costa & Garattini, eds.*), 1009
- Breast enlargement, in Graves' disease, 946-950
- Caffeine content in coffee, affecting glucose metabolism, 539-545
- Calcification of basal ganglia, and excretion of cyclic AMP, 799-807
- Calcitonin secretion by thyroid tumor, and Cushing's syndrome, 831-837
- Calcium
fecal excretion during fasting, 865-874
metabolism during immobilization, 1071-1082
multicompartmental analysis of kinetics, 919-932
urinary excretion
in ketoacidosis of starvation, 502-508
related to sodium excretion, 439-443
- Caloric intake. *See* Diet
- Carbohydrates
dietary
electroretinogram in sucrose-fed rats, 1064-1067
and lipid patterns in serum, 1085-1092
plasma triglyceride response to, 1-16
metabolism of
L-asparaginase affecting, 581-586
in vitro studies of disorders in, 316-323
See also Glucose
- Carboxytolbutamide, hepatic effect of, 1046-1051
- Catalase, absence of, in vitro studies in, 326-327
- Cell cultures, for studies of hereditary metabolic diseases, 309-335
- Ceruloplasmin, zinc bound to, 148-156
- Chediak-Higashi syndrome, in vitro studies of, 331
- Chloride cycles, renal, in aldosteronism, 952-969
- p-Chlorophenoxyisobutyrate, and lipid levels in liver, 120-127
- Chlorpromazine, affecting adenyl cyclase in thyroid slices, 1109-1118
- Cholesterol levels
glucagon affecting, 598-607
in liver, after CPIB, 120-127

- unsaturated dietary fat affecting, 1020-1023
- Circadian rhythms
 - of amino acid excretion, food intake affecting, 363-370
 - of liver glycogen and plasma FFA, food intake affecting, 226-228
 - renal electrolyte cycles in aldosteronism, 952-969
 - of steroid excretion in healthy young men, 341-352
- Cirrhosis, and protein-bound zinc in serum, 148-156
- Citrullinemia, in vitro studies of, 313
- Coffee, caffeine content in, affecting glucose metabolism, 539-545
- Collagen metabolism, in postpartum uterine involution, 19-22
- Colloid droplet formation in thyroid slices, agents affecting, 453-463
- Corticosteroids
 - affecting growth hormone levels, 158-163
 - production affected by cyclic AMP, 1104-1108

See also specific steroids
- Cortisol
 - 2-deoxy-d-glucose infusions affecting levels of, 980-986
 - excretion after diazoxide, blood volume affecting, 469-478
 - and metabolic responses in liver, 562-567
 - production during growth, 280-289
- Cortisone, and metabolic responses in liver, 562-567
- Creatinine excretion, in healthy young men, 341-352
- Cushing's syndrome
 - growth hormone levels in, 158-163
 - remission of, 818-830
 - thymus in, 401-404
 - with thyroid medullary carcinoma, 831-837
- Cyproheptadine, weight gain from, 192-199
- Cystathionuria, in vitro studies of, 316
- Cystic fibrosis of pancreas, in vitro studies of, 333-335
- Cystinosis, in vitro studies of, 327
- Cytidine monophosphate, cyclic, and adrenal steroidogenesis, 1104-1108
- Dehydrogenation, of glucose and xylose, 587-596
- Deoxycholate, affecting glucose-6-phosphatase activity, 349-352
- Diabetes
 - amiloride in, hyperkalemia after, 58-68
 - and early insulin responses to glucose and tolbutamide, 409-416
 - and ethanol effects on glucose-6-phosphatase activity, 349-352
 - experimental, from streptozotocin, 1014-1018
 - follow-up of patients after 25 years, 493-501
 - and Friedreich's ataxia in siblings, 555-559
 - and fucose levels after glucose loading, 114-119
 - in pancreatitis, serum lipids in, 87-89
 - starvation diabetes, 170-177, 271-278
 - and synalbumin insulin antagonist, 668-682
 - thymus in, 401-404

See also Glucose; Insulin
- Dialysis in renal failure, growth hormone levels in, 102-112
- Diazoxide, cortisol excretion after, blood volume affecting, 469-478
- Dichloroacetate sodium, affecting glucose metabolism, 71-77
- Diet
 - affecting amino acid excretion, 363-370
 - affecting diurnal variations in liver glycogen and plasma FFA, 226-228
 - carbohydrates affecting lipid patterns in serum, 1085-1092
 - effects in renal failure, 201-212
 - electroretinogram in sucrose- and starch-fed rats, 1064-1067
 - high fat diet, and liver lipid levels after CPIB, 120-127
 - nitrogen balance in malnutrition, urea affecting, 253-261
 - and plasma triglyceride responses, 1-16
 - salt intake in renal failure, 1053-1062
 - and starvation. *See Fasting*
 - unsaturated fat affecting lipoprotein lipase activity, 1020-1023
- Diisopropylammonium dichloroacetate, affecting glucose metabolism, 71-77
- Diuretics
 - blood volume affecting cortisol excretion after, 469-478
 - complications from, 709-717
 - in diabetes, hyperkalemia from, 58-68
- DNA synthesis in liver, in experimental nephrosis, 392-399
- Electrocardiogram, as index of serum potassium, 68
- Electroretinogram, in sucrose- and starch-fed rats, 1064-1067

- Enteric hormones, affecting insulin secretion, 50-56
- Epinephrine
affecting growth hormone, 547-552
affecting insulin release, 614-618
excretion affected by 2-deoxy-d-glucose infusions, 980-986
and insulin response to D-ribose, 1094-1102
lipolytic action of, growth hormone affecting, 849-854
- Erythrocytes
carbohydrate metabolism defects in, 320-322
glycogen levels, in glycogen storage disease, 238-245
- Ethacrynic acid, complications from, 709-717
- Ethanol
acute intake affecting plasma 11-OCHS levels, 664-667
and glucose-6-phosphatase activity, 349-352
and hepatic fatty acid metabolism, 1036-1043
hypoglycemia from, after thyroxine, 518-526
- Exercise, and insulin production in obesity, 631-636
- Fasting
acidosis after, growth hormone injections in, 608-613
affecting plasma triglycerides, 1-16
amino acid excretion in, 363-370
and body composition changes, 1006-1008
glucose intolerance after, 170-177, 271-278
growth hormone responses in, 174, 176
hyperuricemia in, allopurinol affecting, 84-86
intestinal functions in, 865-874
ketoacidosis of, calcium excretion in, 502-508
natriuresis in, renal tubular sites of, 1119-1127
- Fat cells
lipolysis in, and ATP content, 856-864
preincubation in vitro with T_3 , 480-486
See also Adipose tissue
- Fat, dietary
and liver lipid levels after CPIB, 120-127
plasma triglyceride response to, 1-16
unsaturated, affecting lipoprotein lipase activity, 1020-1023
- Fat metabolism, growth hormone affecting, 849-854
- Fatty acids, free
affecting plasma triglycerides, 1-16
2-deoxy-d-glucose infusions affecting, 980-986
diurnal variation in plasma, food intake affecting, 226-228
epinephrine-induced elevations of, propranolol affecting, 551-552
nicotinic acid affecting, 972-978
raised levels in hyperthyroidism, 93-100
role in diabetes, 681-682
- Fatty liver
from ethanol, 1036-1043
relationship to ATP, 140-146
- Fluoride sodium, affecting thyroid slice metabolism, 35-41
- Follicle-stimulating hormone levels, in myocardial infarction, 79-83
- Food intake
affecting amino acid excretion, 363-370
and diurnal variations in liver glycogen and plasma FFA, 226-228
plasma triglyceride response to, 1-16
See also Diet
- Forbes disease, in vitro studies of, 319
- Friedreich's ataxia, and diabetes in siblings, 555-559
- Fucose levels, and glucose loading in diabetes, 114-119
- Furosemide, complications from, 709-717
- Galactorrhea, from α -methyldopa, 1068-1070
- Galactose metabolism defects, in vitro studies of, 316-317
- Galactosemia, and gal-1-P uridyl transferase in intestinal mucosa, 701-707
- Gardner's syndrome, and excretion of cyclic AMP, 799-807
- Gaucher's disease, in vitro studies of, 328
- Giovannetti diet, modified, in renal failure, 201-212
- Glucagon
affecting anterior pituitary hormone secretion, 904-911
affecting TSH secretion, 488-491
growth hormone response to, 898-902
and plasma lipid transfer to platelets, 598-607
- Glucocorticoids. *See* Corticosteroids
- Glucose
conversion to lipid by adipose tissue, 988-994

- 2-deoxy-d-glucose infusions at bedrest, 980-986
- early insulin responses to, in diabetes, 409-416
- hyperglycemia
from L-asparaginase, 581-586
from mannoheptulose, 354-362
and time sequence of obesity in, 687-693
- hypoglycemia
ethanol-induced, after thyroxine, 518-526
from ketone infusions, 263-269
with nonpancreatic tumors, 445-451
- infusions in hemodialysis, affecting growth hormone levels, 102-112
- ingestion of, and sodium excretion in fasting, 1119-1128
- intolerance after starvation, 170-177, 271-278
- loading in diabetes, and serum fucose levels, 114-119
- metabolism of
affecting insulin release, 614-618
caffeine content in coffee affecting, 539-545
DIPA affecting, 71-77
after jejunioileostomy in obesity, 529-537
- oxidation in thyroid slices, agents affecting, 35-41, 453-463
- plasma triglyceride response to, 1-16
- serum levels
nicotinic acid affecting, 972-978
xylitol infusions affecting, 24-32
- Glucose dehydrogenase, 587-596
- Glucose-6-phosphatase activity, ethanol affecting, 349-352
- Glucose-6-phosphate dehydrogenase, deficiency in red cells, 321-323
- α -Glycerophosphate, hepatic, ethanol affecting, 1036-1043
- Glycogen
liver levels, food intake affecting diurnal variations in, 226-228
metabolism defects, in vitro studies of, 317-320
storage disease, leukocyte phosphorylase in, 238-245
- Goiter
endemic, iodized oil injections in, 569-579
hypothyroidism with, 751-759
See also Thyroid
- Gonadotropin levels, in myocardial infarction, 79-83
- Gout, in vitro studies in, 326
- Granulomatous disease, chronic, in vitro studies of, 331
- Graves' disease, thyroid gland in, 760-771
See also Thyroid
- Growth, and cortisol production rates, 280-289
- Growth hormone
antipolytic effects of, 849-854
arginine infusions affecting, 165-168
L-asparaginase affecting, 581-586
2-deoxy-d-glucose infusions affecting, 980-986
epinephrine affecting, 547-552
glucocorticoids affecting, 158-163
injections in fasting, acidosis after, 608-613
levels in renal failure, 102-112
nicotinic acid affecting, 972-978
propranolol affecting, 406-408, 547-552
release in sleep, 891-896
responses to glucagon and vasopressin, 898-902
role in diabetes, 681-682
starvation affecting, 174, 176
as therapy after destruction of ventromedial hypothalamic nuclei, 995-1003
- Guanosine monophosphate, cyclic, and adrenal steroidogenesis, 1104-1108
- Gynecomastia, in Graves' disease, 946-950
- Hemodialysis, and growth hormone levels, 102-112
- Hepatoma, hypoglycemia with, 445-451
- Hereditary metabolic diseases, studies with leukocyte lysates and cell cultures, 309-335
- Hers disease, in vitro studies of, 320
- Homocystinuria, in vitro studies of, 315-316
- Hunter's syndrome, in vitro studies of, 329-330
- Hurler's syndrome, in vitro studies of, 329-330
- Hydatidiform mole, thyroid stimulator in, 735-743
- Hydrochloric acid, intraduodenal infusion of, affecting insulin levels after portocaval shunts, 214-217
- Hydrocortisone. *See* Cortisol
- β -Hydroxybutyrate infusion, affecting insulin secretion, 263-269
- 17-Hydroxycorticosteroid excretion
during growth and maturation, 280-289
in healthy young men, 341-352
- 11-Hydroxycorticosteroid levels in plasma, acute ethanol intake affecting, 664-667

- Hydroxyproline
 excretion during immobilization, 1071–1082
 peptide, urinary levels after postpartum uterine involution, 19–22
- Hypophysectomy. *See* Pituitary
- Hypothalamus
 destruction of ventromedial nuclei, adipose tissue metabolism after, 995–1003
 lipid mobilizing factor from, 641–650
 stimulation inducing hyperlipidemia, 230–236
- I cell disease, in vitro studies of, 330–331
- Immobilization, affecting bone mineral, 1071–1082
- Infarction, myocardial
 gonadotropin levels in, 79–83
 triglyceride labeling pattern in, 1085–1092
- Injury, and metabolic responses in liver, 562–567
- Inosine monophosphate, cyclic, and adrenal steroidogenesis, 1104–1108
- Insulin
 α -adrenergic blockade affecting levels of, 219–224
 L-asparaginase affecting levels of, 581–586
 2-deoxy-d-glucose infusions affecting levels of, 980–986
 early responses to glucose and tolbutamide in diabetes, 409–416
 enteric hormones affecting levels of, 50–56
 epinephrine and mannoheptulose affecting release of, 614–618
 hepatic uptake after sulfonylureas, 1046–1051
 hyperinsulinemia in obese-hyperglycemic mice, 687–693
 metabolism after jejunioleostomy in obesity, 529–537
 response to carbohydrates, and plasma triglyceride levels, 1–16
 response to glucose, related to caffeine content in coffee, 539–545
 response to D-ribose, 1094–1102
 secretion after starvation, 170–177, 271–278
 serum levels
 in atherosclerosis with hypertriglyceridemia, 372–378
 in obesity, physical training affecting, 631–636
 in portocaval shunts, after intraduodenal infusion of HCl, 214–217
 stimulation of secretion by ketones, 263–269
 synalbumin insulin antagonist, 668–682
 TRIS affecting secretions of, 1011–1013
 urinary excretion of, 301–307
 xylitol affecting levels of, 24–32
- Insulin-like activity
 of growth hormone, 849–854
 nonsuppressible, site of origin of, 509–516
- Intestines
 enteric hormones affecting insulin secretion, 50–56
 functions during fasting, 865–874
 galactose-1-phosphate uridyl transferase in mucosa, 701–707
 jejunioleostomy in obesity, affecting glucose and insulin metabolism, 529–537
- Iodinated substances, in stimulated thyroid glands, 773–783
- Iodine deficiency, chronic, and effects of replacement therapy, 43–49
- Iodized oil injection, in endemic goiter, 569–579
- Iodotyrosine deiodinase, purification from bovine thyroid, 785–798
- Ionic activity, and thyroid slice metabolism, 35–41, 453–463
- Isovaleric acidemia, in vitro studies of, 311
- Jaundice in newborn, and hepatic carriers for bilirubin, 246–252
- Jejunioleostomy in obesity, affecting glucose and insulin metabolism, 529–537
- Ketoacidosis. *See* Acidosis
- Ketone infusions, affecting insulin secretion, 263–269
- Ketonuria, intermittent branched chain, in vitro studies of, 311
- Kidney
 calcium and sodium excretion by, 439–443
 cyclic AMP levels in disorders, vasopressin affecting, 694–700
 dietary treatment in renal failure, 201–212
 electrolyte cycles in aldosteronism, 952–969
 growth hormone levels in renal failure, 102–112
 macromolecule synthesis in experimental nephrosis, 392–399
 phosphate excretion after volume expansion, 129–138
 tubular sites of natriuresis in fasting, 1119–1127
 urea metabolism in renal failure, 1053–1062
 xylitol metabolism in uremia, 24–32

- Lactate metabolism, in tumors with hypoglycemia, 445-451
- Lesch-Nyhan syndrome, in vitro studies of, 325-326
- Leukocytes
 - lysates for studies of hereditary metabolic diseases, 309-335
 - phosphorylase in glycogen storage disease, 238-245
- Leukodystrophy, metachromatic, in vitro studies of, 329
- Lipid
 - glucose conversion to, by adipose tissue, 988-994
 - hyperlipidemia from hypothalamic stimulation, 230-236
 - liver levels of, CPIB affecting, 120-127
 - metabolism in liver, 4-aminopyrazolopyrimidine affecting, 140-146
 - mobilizing factor from hypothalamus, 641-650
 - in plasma, transfer to platelets by glucagon action, 598-607
 - serum levels in pancreatic diabetes, 87-89
 - synthesis by adipose tissue in genetically obese rats, 839-847
- Lipolysis
 - epinephrine action of, growth hormone affecting, 849-854
 - and fat cell ATP content, 856-864
 - in isolated fat cells, T_3 affecting, 480-486
- Lipoprotein
 - orotic acid affecting metabolism of, 1025-1034
 - unsaturated fats affecting activity of, 1020-1023
- Liver
 - amino levulinic acid synthetase levels in pyridoxine deficiency, 189-191
 - 4-aminopyrazolopyrimidine affecting lipid metabolism in, 140-146
 - carrier system for bilirubin, 246-252
 - in ethanol-induced hypoglycemia after thyroxine, 518-526
 - fatty acid metabolism after ethanol, 1036-1043
 - glycogen levels, food intake affecting diurnal variation of, 226-228
 - hepatoma with hypoglycemia, 445-451
 - lipid levels after CPIB, 120-127
 - metabolic responses to injury, 562-567
 - methionine affecting ATP in, 381-389
 - microsomal and soluble fractions, and glucose dehydrogenation, 587-596
 - nephrotic, macromolecule synthesis in, 392-399
 - and sulfonylurea action, 1046-1051
- Luteinizing hormone levels, in myocardial infarction, 79-83
- Lysine, elevated levels of, in vitro studies in, 313
- α_2 -Macroglobulin, zinc bound to, 148-156
- Malnutrition, nitrogen balance in, urea affecting, 253-261
- Mannoheptulose
 - affecting insulin release, 614-618
 - trial in man, 354-362
- Maple syrup urine disease, in vitro studies of, 309-311
- Marfan syndrome, in vitro studies of, 331
- Mastoplasia, in Graves' disease, 946-950
- Methimazole
 - affecting TSH secretion, 488-491
 - thyroid suppression test after, 745-750
- Methionine
 - metabolism defects, in vitro studies of, 315-316
 - pathogenesis of toxicity of, 381-389
- α -Methyldopa, complications from, 1068-1070
- Methylmalonic aciduria, in vitro studies of, 315
- Mineral in bone, immobilization affecting, 1071-1082
- Monophosphates, cyclic, and adrenal steroidogenesis, 1104-1108
 - See also* Adenosine monophosphate
- Morquio's disease, in vitro studies of, 330
- Mucopolysaccharidoses, in vitro studies of, 329-331
- Muscular dystrophy, myotonic, in vitro studies of, 332
- Myocardial infarction
 - gonadotropin levels in, 79-83
 - triglyceride labeling pattern in, 1085-1092
- Nephrosis, experimental, macromolecule synthesis in, 392-399
- Neurophysin, secretion of, 876-889
- Nevus syndrome, basal cell, and excretion of cyclic AMP, 799-807
- Nicotinic acid, affecting growth hormone, FFA and glucose levels, 972-978
- Niemann-Pick's disease, in vitro studies of, 328
- Nitrogen
 - balance in malnutrition, urea affecting, 253-261
 - fecal excretion during fasting, 865-874
- Nocturia, in aldosteronism, 952-969
- Norepinephrine excretion, affected by 2-deoxy-d-glucose infusions, 980-986

- Obesity
 growth hormone levels in, 406-408
 insulin production in, physical training affecting, 631-636
 jejunoileostomy in, affecting glucose and insulin metabolism, 529-537
 lipogenesis in tissue from genetically obese rats, 839-847
 nicotinic acid effects in, 972-978
 oxygen consumption and body composition in, 418-428
 plasma triglyceride levels in, 1-16
 starvation in. *See* Fasting
 and time sequence of hyperglycemia, 687-693
 L-triiodothyronine treatment of, 934-945
Ornithine cycle defects, in vitro studies of, 312-313
Orotic acid, affecting purine and lipoprotein metabolism, 1025-1034
Orotic aciduria, in vitro studies of, 324-325
Osteomalacia, vitamin D-resistant, and excretion of cyclic AMP, 799-807
Oxygen consumption
 and body composition in obesity, 418-428
 in isolated fat cells, T_3 affecting, 480-486
Pancreas
 cystic fibrosis of, in vitro studies of, 333-335
 glucose metabolism in beta cells, affecting insulin release, 614-618
Pancreatitis, diabetes with, serum lipids in, 87-89
Pancreozymin, affecting insulin secretion, 50-56
Parathyroid gland, in hyperthyroidism with hyperparathyroidism, 639-640
Parathyroid hormone, affecting excretion of cyclic AMP, 799-807
Parkinson-like syndrome, from α -methyl-dopa, 1068-1070
Pellagra, abnormal tryptophan metabolism in, 465-467
Pentaerythritol tetranitrate, and hyperlipidemia from hypothalamic stimulation, 230-236
Peptide hydroxyproline, urinary, and postpartum uterine involution, 19-22
pH, affecting amino acids in muscle and plasma, 179-185
Phentolamine, affecting insulin secretion, 219-224
Phosphatases, deficiency of, in vitro studies of, 327
Phosphate excretion, after extracellular fluid volume expansion, 129-138
Phosphoglycerate kinase deficiency, in red cells, 323
Phosphohexose isomerase deficiency, in red cells, 323
Phospholipase C, affecting adenyl cyclase in thyroid slices, 1109-1118
Phospholipogenesis, thyroidal, agents affecting, 35-41
Phosphorus metabolism, during immobilization, 1071-1082
Phosphorylase, leukocyte, in glycogen storage disease, 238-245
Physical training, affecting insulin production in obesity, 631-636
Pituitary
 aminogluthethimide affecting function of, 818-830
 anterior hormone secretion, glucagon affecting, 904-911
 hypophysectomy after destruction of ventromedial hypothalamic nuclei, 995-1003
 neurophysin secretion, 876-889
 nicotinic acid effects in hypopituitarism, 972-978
Platelets, plasma lipid transfer to, by glucagon action, 598-607
Pompe's disease, in vitro studies of, 318-319
Porphyria, experimental, and pyridoxine deficiency, 189-191
Portocaval shunts, and insulin levels after intraduodenal infusion of HCl, 214-217
Posture
 and renal electrolyte cycles in aldosteronism, 960-961
 and sodium and water metabolism in pregnancy, 619-629
Potassium
 deficiency of
 and amino acid content of muscle and plasma, 179-185
 renal cyclic AMP in, vasopressin affecting, 694-700
 hyperkalemia after amiloride in diabetes, 58-68
 metabolism in pregnancy, posture affecting, 619-629
Prednisone, affecting growth hormone levels, 158-163
Pregnancy
 posture affecting sodium and water excretion in, 619-629
 and streptozotocin diabetes, 1014-1018

- urinary peptide hydroxyproline in postpartum uterine involution, 19-22
- Prolidase, affecting hydroxyproline peptide levels, 22
- Propionate degradation defects, in vitro studies of, 313-315
- Propranolol
 - affecting adenylyl cyclase in thyroid slices, 1109-1118
 - affecting growth hormone levels, 406-408, 547-552
 - and insulin response to D-ribose, 1094-1102
- Propylthiouracil, thyroid suppression test after, 745-750
- Prostaglandins
 - and adenylyl cyclase system in thyroid slices, 1109-1118
 - and thyroid metabolism regulation, 453-463
- Protein
 - metabolism after injury, 562-567
 - mixed low-protein diet in renal failure, 201-212
 - serum levels in experimental nephrosis, 392-399
 - synalbumin insulin antagonist, 668-682
 - zinc bound to, 148-156
 - See also* Amino acids
- Purine metabolism
 - in vitro studies of disorders in, 324-326
 - orotic acid affecting, 1025-1034
- Pyridoxine deficiency, and experimental porphyria, 189-191
- Pyrimidine metabolism disorders, in vitro studies of, 324-326
- Pyrophosphate excretion, during immobilization, 1071-1082
- Pyruvate kinase deficiency, in red cells, 323
- Refsum's disease, in vitro studies of, 331-332
- Renal failure. *See* Kidney
- Reserpine, and pituitary-adrenal function, 818-830
- Retina, electrical response of, in sucrose- and starch-fed rats, 1064-1067
- D-Ribose, insulin response to, 1094-1102
- RNA synthesis in liver
 - in experimental nephrosis, 392-399
 - after injury, 562-567
- Saline infusions
 - affecting growth hormone levels, 165-168
 - affecting phosphate excretion, 129-138
 - calcium and sodium excretion after, 439-443
 - and sodium excretion in pregnancy, posture affecting, 619-629
 - and sodium reabsorption in hyponatremia, 291-299
- Salt intake, and urea metabolism in renal failure, 1053-1062
- Sanfillippo syndrome, in vitro studies of, 330
- Scheie syndrome, in vitro studies of, 330
- Secretin, affecting insulin secretion, 50-56
- Sickle hemoglobin, and renal cyclic AMP levels, vasopressin affecting, 694-700
- Sleep, growth hormone release in, 891-896
- Sodium
 - excretion related to calcium excretion, 439-443
 - glucose affecting excretion of, 1119-1128
 - hyponatremia from diuretics, 709-717
 - levels in fasting, after growth hormone injection, 608-613
 - metabolism in pregnancy, posture affecting, 619-629
 - reabsorption in hyponatremia, saline infusions affecting, 291-299
 - renal cycles in aldosteronism, 952-969
 - renal tubular sites of natriuresis in fasting, 1119-1127
 - salt intake in renal failure, 1053-1062
- Spermidine, in nephrotic liver, 392-399
- Sphingolipidoses, in vitro studies of, 328-329
- Spielmeyer-Vogt disease, in vitro studies of, 329
- Spirolactone, in diabetes, hyperkalemia from, 68
- Starch-fed rats, electroretinogram in, 1064-1067
- Starvation. *See* Fasting
- Steroidogenesis, affected by cyclic monophosphates, 1104-1108
- Streptozotocin diabetes, 1014-1018
- Sucrose-fed rats, electroretinogram in, 1064-1067
- Sulfonylureas, hepatic effect of, 1046-1051
- Synalbumin insulin antagonist, 668-682
- Tay-Sach's disease, in vitro studies of, 328-329
- Thymus, in endocrinologic disorders, 401-404
- Thyrocalcitonin excess syndrome, 639-640
- Thyroid
 - agents affecting adenylyl cyclase activity in slices, 430-437, 1109-1118
 - endemic goiter in Greece, 569-579
 - extract in chronic iodine deficiency, 43-49
 - gynecomastia and mastoplasia in Graves' disease, 946-950

- hyperthyroidism
 - free fatty acid levels in, 93-100
 - function studies in Graves' disease, 760-771
 - growth hormone levels in, 406-408
 - with hyperparathyroidism, 639-640
- hypothyroidism with goiter, 751-759
- iodinated substances in stimulated glands, 773-783
- medullary carcinoma with Cushing's syndrome, 831-837
- metabolism in, thyrotropin affecting, 35-41, 453-463
- purification of iodotyrosine deiodinase from bovine thyroid, 785-798
- suppression test after therapy, 745-750
- Thyroid stimulator, long-acting
 - activity in Graves' disease, 760-771
 - affecting adenyl cyclase in thyroid slices, 430-437
 - affecting thyroid membrane potential, 724-733
 - and breast enlargement in Graves' disease, 946-950
- Thyrotropin
 - and adenyl cyclase system in thyroid slices, 1109-1118
 - affecting thyroid membrane potential, 724-733
 - affecting thyroid slice metabolism, 35-41
 - attempts to augment secretion of, 488-491
 - levels in chronic iodine deficiency, 43-49
 - molar, 735-743
 - and thyroid metabolism regulation, 35-41, 453-463
 - thyroid responses to, in Graves' disease, 770-771
- Thyroxine
 - and ethanol-induced hypoglycemia, 518-526
 - and fatty liver from ethanol, 1036-1043
- Tolazamide, hepatic effect of, 1046-1051
- Tolbutamide
 - early insulin responses to, in diabetes, 409-416
 - hepatic effect of, 1046-1051
- Transferrin, zinc bound to, 148-156
- Triglycerides
 - hypertriglyceridemia with atherosclerosis, insulin levels in, 372-378
 - labeling pattern after myocardial infarction, 1085-1092
 - liver levels
 - after CPIB, 120-127
 - ethanol affecting, 1036-1043
 - plasma levels
 - response to carbohydrates, fats and caloric intake, 1-16
 - unsaturated dietary fats affecting, 1020-1023
- Trihydroxymethylaminomethane (TRIS), affecting insulin secretion, 1011-1013
- Triiodothyronine
 - affecting adipose tissue in vitro, 480-486
 - in obesity, 934-945
- Triosephosphate isomerase deficiency, in red cells, 323
- Tryptophan metabolism, abnormal, in pel-lagra, 465-467
- Tumors
 - adrenal, ACTH-responsive, adenyl cyclase from, 809-817
 - nonpancreatic, hypoglycemia with, 445-451
 - thyroid medullary carcinoma, with Cush-ing's syndrome, 831-837
- Urea
 - metabolism in chronic renal failure, 1053-1062
 - and nitrogen balance in malnutrition, 253-261
- Uremia. *See* Kidney
- Uric acid levels, elevated in fasting, allo-purinol affecting, 84-86
- Uridine monophosphate, cyclic, and adrenal steroidogenesis, 1104-1108
- Uterus, postpartum involution of, and uri-nary peptide hydroxyproline levels, 19-22
- Valine, elevated levels of, in vitro studies of, 311-312
- Vasopressin
 - affecting renal cyclic AMP in disorders, 694-700
 - affecting TSH secretion, 488-491
 - growth hormone response to, 898-902
- Vitamin D-resistant osteomalacia, and excre-tion of cyclic AMP, 799-807
- Water metabolism in pregnancy, posture af-fecting, 619-629
- Weight
 - decline of lean body mass with age, 653-661
 - gain from cyproheptadine, 192-199
- Weightlessness, absolute bedrest as study of, 980-986
- Xylitol metabolism, 24-32
- Xylose dehydrogenation, 587-596
- Zinc, protein-bound, distribution in serum, 148-156

Notes to Contributors

Original Communications. Manuscripts for publication, letters and all other editorial communications should be addressed to the Editor-in-Chief, at the address given on page iv. Articles are accepted for publication on the condition that they are contributed solely to this Journal. Contributors should bear in mind the nature of the Journal, i.e., articles should have a definite metabolic application, with case reports submitted only if they include controlled observations of an exceptionally revealing nature. Papers should be as brief as possible, consistent with the subject.

The original copy and one duplicate should be submitted (table and figures also to be submitted, if possible, in duplicate). Contributions should include a page giving the authors' degrees and hospital and academic affiliations and an address for mailing proofs.

Preliminary Reports. Contributors are encouraged to submit articles in a special short form to be known as a "Preliminary Report," with the understanding that if such an article is accepted it will be printed in the next available issue, regardless of the backlog of regular articles. A "Preliminary Report" can serve as a preliminary report on work just completed, or may be a final report or an observation which does not require a lengthy write-up. To qualify for the priority given a Preliminary Report the article must not exceed 1000 words including the bibliography and can have no more than one simple table or small figure. If a figure or table is included the author should cut the 1000 words allowance by an amount sufficient to allow for the space which will be taken up by the table or figure, as no Preliminary Report may take up more than two pages in the Journal. Despite the limitations on length, data to support the conclusions stated should be included to the extent necessary.

Manuscripts should be typewritten on good quality paper, one side of the page only, with double or triple spacing and

liberal margins throughout. Handwritten manuscripts, single-spaced material, and excessive interlineated corrections are unacceptable. References to the literature should follow the style of the Journal and be compiled at the end of the article in numerical sequence.

Illustrations and Tables. Position of figures and tables in the text should be marked on manuscript. METABOLISM uses arabic rather than roman numbering. Figures should carry their number and the author's name on the back; figure legends should be compiled in a separate list. To ensure clear reproduction, all copy for zinc cuts, including pen drawings and charts, should be prepared with black india ink, and a black ribbon should be used for typewritten material; for half-tone work, good photographic prints or the original drawings should be supplied. Graphs should be drawn on plain white or blue-lined graph paper. Tables and illustrations should be of a size easily handled, and for all illustrations the effect of possible reduction in size to fit the Journal page should be considered.

Four illustrations and a total of one and one-half printed pages of tables are allowed gratis per article, with the contributor bearing the cost in excess of these limits; excessive engravings are charged for at \$10.00 each, excessive tables at about \$30.00 per page. The contributor must likewise bear all costs connected with printing color plates.

Proofreading. Contributors are provided with galley proofs and are asked to proofread them for typesetting errors. Important changes in data are allowed within reason without cost, but excessive alterations and additions must be charged to the contributor.

Reprints. Reprints of articles will be furnished to contributors when ordered in advance of publication. An order form, showing cost of reprints, is sent with proofs. Individual reprints of an article can usually be obtained by writing directly to its author (see footnote on first page).

A new
diagnostic agent
for the
rapid screening
of adrenal
insufficiency based
on the plasma
cortisol response